Bio-Techne (TECH) EBIT (2009 - 2026)

Bio-Techne has reported EBIT for 18 years, with the latest figure at $74.3 million in Q2 2026.

• On a quarterly basis, EBIT rose 411.3% year-over-year to $74.3 million in Q2 2026; TTM through Jun 2026 was $251.9 million, a 146.34% increase from a year earlier, with the FY2026 full-year figure at $251.9 million, up 146.34% from the prior year.
• EBIT was $74.3 million for Q2 2026 at Bio-Techne, down from $75.5 million in the prior quarter.
• The five-year high for EBIT was $94.5 million in Q2 2023, with the low at -$23.9 million in Q2 2025.
• Average EBIT over 5 years is $57.3 million, with a median of $56.1 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: EBIT slumped 152.07% in 2025, then surged 411.3% in 2026.
• Over 5 years, EBIT stood at $67.9 million in 2022, then tumbled by 44.02% to $38.0 million in 2023, then increased by 24.77% to $47.4 million in 2024, then climbed by 14.85% to $54.5 million in 2025, then jumped by 36.38% to $74.3 million in 2026.
• The last three EBIT figures came in at $74.3 million (Q2 2026), $75.5 million (Q1 2026), and $54.5 million (Q4 2025), per Business Quant data.